Effects of low molecular weight heparins and unfractionated heparin on viability of human umbilical vein endothelial cells

Archives of Gynecology and Obstetrics

Volumn 287, Issue 2, 2013, Pages 217-222

  Guler, Tolga ^a   Polat, Zubeyde Akin ^b   Yayci, Eyup ^a   Atacag, Tijen ^a   Cetin, Ali ^a  

^a NEAR EAST UNIVERSITY   (Turkey)

^b CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Bemiparin; Endothelial cells; Enoxaparin; Heparin; Human umbilical vein; Nadroparin; Survivability

Indexed keywords

BEMIPARIN; ENOXAPARIN; HEPARIN; NADROPARIN;

ARTICLE; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NADROPARIN;

EID: 84878349730     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2558-1     Document Type: Article

References (23)

1. Ludwig RJ (2009) Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol 6(4):281-289
2. Borsig L (2007) Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Semin Thromb Hemost 33(5):540-546
3. Viero S, Chaddha V, Alkazaleh F, Simchen MJ, Malik A, Kelly E, Windrim R, Kingdom JC (2004) Prognostic value of placental ultrasound in pregnancies complicated by absent end-diastolic flow velocity in the umbilical arteries. Placenta 25(8-9):735-741
4. Cheng MH, Wang PH (2009) Placentation abnormalities in the pathophysiology of preeclampsia. Expert Rev Mol Diagn 9(1):37-49
5. Pérez-Ruiz A, Montes R, Carrasco P, Rocha E (2002) Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium. Clin Appl Thromb Hemost 8(1):65-71
6. Martinez-Sales V, Vila V, Réganon E, Oms JG, Aznar J (2003) Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells. Haematologica 88(6):694-699
7. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F (1999) Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 19(9):2251-2262
8. Krause BJ, Prieto CP, Muñoz-Urrutia E, San Martín S, Sobrevia L, Casanello P (2012) Role of arginase-2 and eNOS in the differential vascular reactivity and hypoxia-induced endothelial response in umbilical arteries and veins. Placenta 33(5):360-366
9. Liao WX, Laurent LC, Agent S, Hodges J, Chen DB (2012) Human Placental Expression of SLIT/ROBO Signaling Cues: effects of Preeclampsia and Hypoxia. Biol Reprod 86(4):111
10. Prieto CP, Krause BJ, Quezada C, San Martin R, Sobrevia L, Casanello P (2011) Hypoxia-reduced nitric oxide synthase activity is partially explained by higher arginase-2 activity and cellular redistribution in human umbilical vein endothelium. Placenta 32(12):932-940
11. Kujovich JL (2004) Thrombophilia and pregnancy complications. Am J Obstet Gynecol 191(2):412-424
12. Sibai B, Dekker G, Kupferminc M (2005) Pre-eclampsia. Lancet 365(9461):785-799
13. Greer IA (1999) Thrombosis in pregnancy: maternal and fetal issues. Lancet 353(9160):1258-1265
14. Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, Kahn SR, Magee LA, Rodger M (2009) Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 7(1):58-64
15. Gris JC, Chauleur C, Faillie JL, Baer G, Marès P, Fabbro-Peray P, Quéré I, Lefrant JY, Haddad B, Dauzat M (2010) Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 104(4):771-779
16. Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, Acaia B, Facchinetti F, La Sala GB, Bozzo M, Rampello S, Marozio L, Diadei O, Gherardi G, Carminati S, Remuzzi G, Mannucci PM (2012) Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 119(14):3269-3275
17. Shamshirsaz AA, Paidas M, Krikun G (2012) Preeclampsia, hypoxia, thrombosis, and inflammation. J Pregnancy 2012:374047
18. Young E (2008) The anti-inflammatory effects of heparin and related compounds. Thromb Res 122(6):743-752
19. Gasowska K, Naumnik B, Klejna K, MyÅliwiec M (2009) The influence of unfractionated and low-molecular weight heparins on the properties of human umbilical vein endothelial cells (HUVEC). Folia Histochem Cytobiol 47(1):17-23
20. Verlohren S, Stepan H, Dechend R (2012) Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond) 122(2):43-52
21. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ (1997) Regulation of human placental development by oxygen tension. Science 277(5332):1669-1672
22. Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A (2008) Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 121(5):637-645
23. Mousa SA, Mohamed S (2004) Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 92(3):627-633